Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

[1]  N. Klimas,et al.  Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:PolyC12U in the treatment of HIV infection , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  M. Jefford,et al.  The use of dendritic cells in cancer therapy. , 2001, The Lancet. Oncology.

[3]  S. H. van der Burg,et al.  Natural T‐helper immunity against human papillomavirus type 16 (hpv16) e7–derived peptide epitopes in patients with hpv16‐positive cervical lesions: Identification of 3 human leukocyte antigen class ii–restricted epitopes , 2001, International journal of cancer.

[4]  S. Fisher,et al.  A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[6]  R. Steinman,et al.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.

[7]  R. Verdijk,et al.  Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. , 1999, Journal of immunology.

[8]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[9]  C. Meijer,et al.  Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. , 1998, Cancer research.

[10]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[11]  L. Borysiewicz,et al.  Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. , 1997, Cancer research.

[12]  E. Gilboa,et al.  Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts , 1997, International journal of cancer.

[13]  S. Stacey,et al.  A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer , 1996, The Lancet.

[14]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[15]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[16]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[17]  P. Lambert,et al.  Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[19]  V. Devita,et al.  A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. , 1976, Journal of the National Cancer Institute.